There are currently 6 active clinical trials seeking participants for Carcinoma, Renal Cell research studies. The states with the highest number of trials for Carcinoma, Renal Cell participants are California, Texas, New York and Florida.
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
NCT04895709
Recruiting
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab or docetaxel in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Community Cancer Institute, Clovis, California +49 locations
Conditions: Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Urothelial Carcinoma, Pancreatic Adenocarcinoma, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms
Register for Updates
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
NCT05544929
Recruiting
The purpose of this study is to characterize the safety and tolerability of KFA115 and KFA115 in combination with pembrolizumab in patients with select advanced cancers, and to identify the maximum tolerated dose and/or recommended dose.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
07/10/2025
Locations: Massachusetts General Hospital ., Boston, Massachusetts +17 locations
Conditions: Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial, Nasopharyngeal Carcinoma, Carcinoma, Thymic, Anal Cancer, Mesothelioma, Esophagogastric Cancer, High Microsatellite Instability Colorectal Carcinoma, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Neoplasms
Register for Updates
Autologous Dendritic Cell Vaccine in Kidney Cancer
NCT05127824
Recruiting
The purpose of this study is to estimate the probability of immune response for the combination treatment of dendritic cell vaccine with oral cabozantinib and characterize the safety profile of interventional therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: UPMC Department of Urology, Pittsburgh, Pennsylvania
Conditions: Carcinoma, Renal Cell
Register for Updates
Exploring Relevant Immune-based Biomarkers and Circulating Tumor Cells During Treatment With Immunotherapy in Genitourinary Malignancies (CTC Immune Based Biomarkers)
NCT02978118
Recruiting
This pilot study purpose of this study is to describe peripheral circulating immune cell profiles at baseline and change on treatment with immune checkpoint inhibitors in renal cell carcinoma and urothelial carcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/13/2025
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Carcinoma, Renal Cell, Carcinoma, Urothelial
Register for Updates
Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination with Sunitinib in Patients with TKIs-resistant RCC
NCT06222593
Recruiting
This is a Phase I/II open-label, efficacy and safety study of bicalutamide in combination with sunitinib in patients with advanced renal cell carcinoma (RCC) who have been treated with a receptor tyrosine kinase inhibitor (RTKI) and experienced disease progression.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: UB/ Great Lakes Cancer Care, Buffalo, New York
Conditions: Carcinoma, Renal Cell
Register for Updates
Mass Response of Tumor Cells As a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
NCT05461430
Recruiting
The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from various specimen formats including malignant fluids such as pleural effusions and ascites, core needle biopsies, fine needle aspirates, or resections.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/21/2024
Locations: xCures, Oakland, California
Conditions: Pleural Effusion, Malignant, Ascites, Malignant, Carcinoma, Carcinoma, Hepatocellular, Carcinoma, Renal Cell, Carcinoma, Renal, Carcinoma, Small Cell, Carcinoma, Non-Small-Cell Lung, Carcinoma, Pancreatic Ductal, Carcinoma, Neuroendocrine, Carcinoma, Thymic, Carcinoma, Pancreatic, Carcinoma Breast, Carcinoma, Ovarian, Carcinoma Bladder, Carcinoma of Unknown Primary, Carcinoma of the Head and Neck, Carcinoma of the Oropharynx, Carcinoma of the Larynx, Carcinoma of the Bladder, Carcinoma of Esophagus, Carcinoma of the Nasopharynx, Carcinoma of the Penis, Carcinoma of the Cervix, Carcinoma of the Anus, Carcinoma of the Vulva, Carcinoma of the Appendix, Carcinoma of the Oral Cavity, Cholangiocarcinoma, Melanoma, Mesothelioma, Pancreatic Cancer
Register for Updates